Multiple Sclerosis and Related Disorders

Papers
(The H4-Index of Multiple Sclerosis and Related Disorders is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms108
Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States80
Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report77
Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis72
Long COVID or post COVID-19 syndrome65
COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review64
Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study60
Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review57
Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis56
Can coronavirus disease 2019 (COVID-19) trigger exacerbation of multiple sclerosis? A retrospective study53
COVID-19 in ocrelizumab-treated people with multiple sclerosis52
OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis48
MOG-associated encephalitis following SARS-COV-2 infection47
The Symbol Digit Modalities Test (SDMT) is sensitive but non-specific in MS: Lexical access speed, memory, and information processing speed independently contribute to SDMT performance47
COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 202144
A candidate biomarker of glial fibrillary acidic protein in CSF and blood in differentiating multiple sclerosis and its subtypes: A systematic review and meta-analysis43
Autoimmune encephalitis associated with COVID-19: A systematic review42
COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect?42
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis42
Effectiveness of Virtual Reality Rehabilitation in Persons with Multiple Sclerosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials40
Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases39
Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England38
Fear of falling and falls in people with multiple sclerosis: A literature review38
Upper limb rehabilitation interventions using virtual reality for people with multiple sclerosis: A systematic review38
COVID-19 vaccine associated demyelination & its association with MOG antibody37
Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: A systematic review and meta-analysis37
Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients37
Chronic fatigue and depression due to multiple sclerosis: Immune-inflammatory pathways, tryptophan catabolites and the gut-brain axis as possible shared pathways37
COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies37
Multiple sclerosis and aging: comorbidity and treatment challenges36
COVID-19 and emerging spinal cord complications: A systematic review36
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis36
Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy36
COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America35
Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis34
The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity34
0.06689190864563